Welcome to this UK AstraZeneca produced and funded website

This website is intended for UK Healthcare Professionals only.

 

The website contains both promotional and non-promotional content.

 

If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk

 

For any other UK residents please visit astrazeneca.co.uk

I am not a Healthcare Professional
IMFINZI (durvalumab) UK Prescribing Information
IMJUDO (tremelimumab) ▼ UK Prescribing Information
Adverse Event Reporting

This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk

AstraZeneca-logo
  • Our Medicines
    • Cardiovascular, Renal & Metabolism
      • ATTR Amyloidosis
        • WAINZUA®▼(eplontersen)
      • Chronic Kidney Disease (CKD)
        • FORXIGA® (dapagliflozin)
      • Heart Failure
        • FORXIGA® (dapagliflozin)
      • Hyperkalaemia
        • LOKELMA® (sodium zirconium cyclosilicate)
      • Type 2 Diabetes (T2D)
        • FORXIGA® (dapagliflozin)
    • Oncology
      • Breast Cancer
        • LYNPARZA® (olaparib)
        • TRUQAP®▼(capivasertib)
      • Bladder Cancer
        • IMFINZI® (durvalumab)
      • Endometrial Cancer
        • IMFINZI® (durvalumab)
        • LYNPARZA® (olaparib)
      • Gastrointestinal Cancer
        • IMFINZI® (durvalumab)
        • IMJUDO®▼(tremelimumab)
      • Lung Cancer
        • IMFINZI® (durvalumab)
        • TAGRISSO® (osimertinib)
      • Ovarian Cancer
        • LYNPARZA® (olaparib)
      • Prostate Cancer
        • LYNPARZA® (olaparib)
        • ZOLADEX® (goserelin)
    • Respiratory
      • Asthma
        • TEZSPIRE®▼ (tezepelumab)
        • SYMBICORT® (budesonide/formoterol)
      • Chronic Obstructive Pulmonary Disease(COPD)
        • TRIXEO AEROSPHERE® (formoterol fumarate dihydrate/glycopyrronium/budesonide)
        • BEVESPI® (glycopyrronium/formoterol fumarate dihydrate)
    • Vaccines
      • Flu
        • FLUENZ® nasal spray suspension (influenza vaccine, live attenuated, nasal)
  • Therapy Areas
    • Cardiovascular, Renal & Metabolism
      • ATTR Amyloidosis
      • Chronic Kidney Disease (CKD)
      • Heart Failure
      • Hyperkalaemia
      • Type 2 Diabetes (T2D)
    • Oncology
      • Breast Cancer
      • Bladder Cancer
      • Endometrial Cancer
      • Gastrointestinal Cancer
      • Lung Cancer
      • Ovarian Cancer
      • Prostate Cancer
    • Respiratory
      • Asthma
      • Chronic Obstructive Pulmonary Disease(COPD)
    • Vaccines
      • Flu
  • About us
    • AZ Commitment
  • Contact us
  • AstraZeneca UK
  • IMFINZI (durvalumab)
  • Resources
  • Biliary Tract Cancer (BTC) Care
  • Home
  • Biliary tract cancer
    • About biliary tract cancer
    • Mode of action
    • TOPAZ-1 clinical trial
    • Dosing & administration
    • Resources
  • Hepatocellular carcinoma
    • Why STRIDE?
    • About hepatocellular carcinoma
    • Mode of action
    • HIMALAYA clinical trial
    • Dosing & administration
    • Resources
  • Resources
    • Biliary tract cancer resources
    • Hepatocellular carcinoma resources
    • Gastrointestinal cancer resources
Biliary Tract Cancer (BTC) Care

< Back to resources

Biliary Tract Cancer (BTC) Care: A guide to supporting patient fitness and performance status to help optimise outcomes.

This is a guide to support Healthcare Professionals (HCPs) in optimising patient fitness with practical strategies on managing bilirubin, supporting nutrition, enhancing physical activity, and driving effective multi-disciplinary team collaboration to help deliver improved outcomes.

 

READ ONLINE REQUEST A COPY

GB-73000 | January 2026

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.

Connessiallasalute.it

This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Terms of use

Privacy Policy

Cookie Policy

Contact Us

LinkedIn

Twitter

©2026 AstraZeneca. GB-76920 | May 2026

Enhance your knowledge, stay informed

Be the first to know. Hear about events, products and ways to support your patients.

Thank you. We will be in touch

GB-74216| DOP : February 2026